Novartis receives European Commission approval for Rhapsido skin disease drug

Novartis has received European ​Commission approval ‌for its drug Rhapsido, an ​oral treatment ​for chronic spontaneous urticaria (CSU), ⁠the Swiss ​drugmaker said ​on Monday.